LA JOLLA PHARMACEUTICAL CO (LJPC) Stock Price, Forecast & Analysis
NASDAQ:LJPC • US5034596040
LJPC Key Statistics, Chart & Performance
The current stock price of LJPC is 6.22 USD. In the past month the price increased by 0.48%. In the past year, price increased by 68.11%.
LJPC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LJPC. When comparing the yearly performance of all stocks, LJPC is one of the better performing stocks in the market, outperforming 98.66% of all stocks.
LJPC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LJPC. While LJPC is still in line with the averages on profitability rating, there are concerns on its financial health.
LJPC Financial Highlights
Over the last trailing twelve months LJPC reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.54% | ||
| ROA | 3.99% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
LJPC Forecast & Estimates
6 analysts have analysed LJPC and the average price target is 6.35 USD. This implies a price increase of 2.16% is expected in the next year compared to the current price of 6.22.
For the next year, analysts expect an EPS growth of -92.84% and a revenue growth -31.93% for LJPC
LJPC Ownership
LJPC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.54 | 390.397B | ||
| AMGN | AMGEN INC | 16.33 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.08 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.79 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.89 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.8 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.77 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LJPC
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
Company Info
LA JOLLA PHARMACEUTICAL CO
201 Jones Road, Suite 400
Waltham MASSACHUSETTS 92121 US
CEO: Larry Edwards
Employees: 61
Phone: 16177153600.0
LA JOLLA PHARMACEUTICAL CO / LJPC FAQ
What does LA JOLLA PHARMACEUTICAL CO do?
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
Can you provide the latest stock price for LA JOLLA PHARMACEUTICAL CO?
The current stock price of LJPC is 6.22 USD.
What is the dividend status of LA JOLLA PHARMACEUTICAL CO?
LJPC does not pay a dividend.
What is the ChartMill technical and fundamental rating of LJPC stock?
LJPC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is LJPC stock listed?
LJPC stock is listed on the Nasdaq exchange.
Is LA JOLLA PHARMACEUTICAL CO (LJPC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LJPC.
Can you provide the market cap for LA JOLLA PHARMACEUTICAL CO?
LA JOLLA PHARMACEUTICAL CO (LJPC) has a market capitalization of 158.96M USD. This makes LJPC a Micro Cap stock.